Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Dow Jones Industrial Average ETF (DIA) vs Neurocrine Biosciences Inc (NBIX) Price & Performance

Dow Jones Industrial Average ETFTrade
Neurocrine Biosciences IncTrade

Price performance (Past 24H)

Key statistics

Dow Jones Industrial Average ETF vs Neurocrine Biosciences Inc — how do they compare? Dow Jones Industrial Average ETF trades at $537.61, while Neurocrine Biosciences Inc trades at $156.83 (market cap $16.46B). The key difference: Dow Jones Industrial Average ETF is trading nearer its 52-week high, Neurocrine Biosciences Inc nearer its low. Which is the better fit depends on your goals.

DIANBIX
52-Week High
$542.79$185.50
52-Week Low
$444.64$123.10
Market Cap
$16.46B
Sector
Health
Enterprise Value
$16.48B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Dow Jones Industrial Average ETF

DIA trades at $537.63, down 0.25% on the day, with a bullish technical signal driven by moving averages. The stock is near its pivot point of $539, with support at $536 and resistance at $540. Recent dividends include H1-26 payments of $1.41 and $0.28, with another $0.15 scheduled for H2-26.

The outlook is supported by broad market momentum and defensive ETF inflows, though overbought RSI levels suggest near-term caution. Key risks include market volatility and interest rate sensitivity. Analyst sentiment is generally positive given the Dow's performance and institutional interest in blue-chip exposure.

Neurocrine Biosciences Inc

Neurocrine Biosciences (NBIX) trades at $158.89, down 3.66% in the past 24 hours, reflecting near-term bearish technical signals. The stock shows strong fundamentals with Q2 2026 revenue growth of 39% year-over-year to $959 million and a net income margin of 20.91%. Recent news highlights include positive clinical data for INGREZZA and the initiation of a Phase 1 study for a GLP-1/GIP/glucagon receptor triple agonist, though safety concerns were raised for Vykat XR in Prader-Willi Syndrome.

The outlook remains positive given robust earnings beats, raised 2026 sales guidance, and a consensus price target of $208.82 implying significant upside. Risks include clinical trial setbacks, competitive pressures, and regulatory scrutiny. Analyst sentiment is strongly bullish with 86% buy ratings, supporting a growth-oriented investment case amid near-term volatility.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Dow Jones Industrial Average ETF

The ETF is designed to track the performance of the securities and the stocks in the Dow Jones Industrial Average Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.

Read more on DIA

About Neurocrine Biosciences Inc

Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.

Read more on NBIX